The more Americans that take Ozempic, the faster the US economy will grow, Goldman Sachs says
Goldman estimates that anywhere from 10 million to 70 million Americans will be taking a GLP-1 drug by 2028, with the wide range being driven by uncertainties related to adequate supply, insurance coverage, and clinical trial outcomes.
“If GLP-1 usage ultimately increases by this amount and results in lower obesity rates, we see scope for significant spillovers to the broader economy,” Hatzius said.
One spillover effect would be an increase in productivity. Hatzius cited academic studies that show obese individuals are both less likely to work and less productive when they do work.
It is also tied to the ClimateCrisis: Lighter people need less energy to move or be moved by transport, and consume less food. At some point, if you are not at an ideal weight, medicated weight loss will become mandatory.
Many employers already have surcharges to those not meeting specified health metric targets.
It’s Just Science, of course.
